Upendra P Dahal
Overview
Explore the profile of Upendra P Dahal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang D, Manoni F, Sun Z, Liu R, Allen J, Banerjee A, et al.
J Med Chem
. 2025 Feb;
68(4):4801-4817.
PMID: 39930787
Covalent inhibition of the KRAS oncoprotein has emerged as a promising therapeutic approach for the treatment of nonsmall cell lung cancer (NSCLC). The identification of KRAS inhibitors has typically relied...
2.
Farhan N, Dahal U, Wahlstrom J
J Clin Pharmacol
. 2024 Jun;
64(10):1222-1235.
PMID: 38898531
Uridine 5'-diphospho-glucuronosyltransferases (UGTs) demonstrate variable expression in the pediatric population. Thus, understanding of age-dependent maturation of UGTs is critical for accurate pediatric pharmacokinetics (PK) prediction of drugs that are susceptible...
3.
Wang M, Kuldharan S, Shenoy A, Reddy S, Rex K, Osgood T, et al.
Drug Metab Dispos
. 2024 Apr;
52(7):644-653.
PMID: 38670798
Free (unbound) drug concentration at the site of action is the key determinant of biologic activity since only unbound drugs can exert pharmacological and toxicological effects. Unbound drug concentration in...
4.
Payton M, Belmontes B, Hanestad K, Moriguchi J, Chen K, McCarter J, et al.
Nat Cancer
. 2023 Dec;
5(1):66-84.
PMID: 38151625
Chromosomal instability (CIN) is a hallmark of cancer, caused by persistent errors in chromosome segregation during mitosis. Aggressive cancers like high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC)...
5.
Coutant D, Boulton D, Dahal U, Deslandes A, Grimaldi C, Pereira J, et al.
Clin Pharmacol Ther
. 2022 Dec;
113(6):1185-1198.
PMID: 36477720
Typically, therapeutic proteins (TPs) have a low risk for eliciting meaningful drug interactions (DIs). However, there are select instances where TP drug interactions (TP-DIs) of clinical concern can occur. This...
6.
Vuu I, Dahal U, Wang Z, Shen X, Rodgers J, Wahlstrom J, et al.
Cancer Chemother Pharmacol
. 2022 Sep;
90(4):357-367.
PMID: 36063185
Purpose: The objectives of this study were to characterize the absorption, metabolism, and excretion of sotorasib and determine the metabolites present in plasma, urine, and feces in healthy male subjects...
7.
Tamayo N, Bourbeau M, Allen J, Ashton K, Chen J, Kaller M, et al.
J Med Chem
. 2022 Mar;
65(6):4972-4990.
PMID: 35286090
Chromosomal instability (CIN) is a hallmark of cancer that results from errors in chromosome segregation during mitosis. Targeting of CIN-associated vulnerabilities is an emerging therapeutic strategy in drug development. KIF18A,...
8.
Dahal U, Rock B, Rodgers J, Shen X, Wang Z, Wahlstrom J
Drug Metab Dispos
. 2022 Feb;
50(5):600-612.
PMID: 35153196
Sotorasib is a first-in-class, targeted covalent inhibitor of Kirsten rat sarcoma viral oncogene homolog (KRAS) approved by the FDA to treat patients with locally advanced or metastatic non-small cell lung...
9.
Werner J, Davies R, Wahlstrom J, Dahal U, Jiang M, Stauber J, et al.
Toxicol Appl Pharmacol
. 2021 May;
423:115578.
PMID: 34004237
Sotorasib is a first-in class KRAS covalent inhibitor in clinical development for the treatment of tumors with the KRAS p.G12C mutation. In the nonclinical toxicology studies of sotorasib, the kidney...
10.
Barr J, Tran T, Rock B, Wahlstrom J, Dahal U
Drug Metab Dispos
. 2020 Jun;
48(8):613-621.
PMID: 32474442
Drug discovery programs routinely perform pharmacokinetic (PK) studies in mice to prioritize lead compounds based on anticipated exposure-efficacy and exposure-toxicity relationships. Because of logistical and/or technical issues, the strain of...